Aranapakam Venkatesan

Aranapakam Venkatesan has extensive work experience in the pharmaceutical industry. Aranapakam is currently working as a Vice President at Elucida Oncology, Inc. since May 2019. Prior to this, they served as the Director of Medicinal Chemistry & Custom Synthesis at TCG Lifesciences starting from October 2014.

Venkatesan's previous experience includes working as an Associate Director of Medicinal Chemistry at Endo Pharmaceuticals from July 2010 to December 2013. During their time at Endo Pharmaceuticals, they managed and supervised medicinal chemists at four CROs in India. Aranapakam invented a novel and patentable linker system for targeted delivery of highly potent cytotoxic payloads. Aranapakam also led the medicinal chemistry efforts in inventing a small molecule for the treatment of rheumatoid arthritis and was involved in the discovery of a Cyp17 Inhibitor for the treatment of castration-resistant prostate cancer.

Venkatesan's earlier career includes working as a Principal Research Scientist at Wyeth Research/ Pfizer from September 1989 to 2010, and as a Research Scientist at American Cyanamid Company from 1989 to 1995.

Aranapakam Venkatesan has a Post Doctoral Research in Synthetic Organic Chemistry from Columbia University. Additionally, they hold a Doctor of Philosophy (Ph.D.) in Synthetic Organic Chemistry from New York University. The duration of their education at both these institutions is unspecified.